Dr Ada Kruisbeek resigns as CSO, assumes role as Chair of the Scientific Advisory Board


HomeHomeDr Ada Kruisbeek resigns as CSO, assumes role as Chair of the Scientific Advisory Board

Leiden, The Netherlands, January 2019 – DCprime announces that Dr Ada Kruisbeek, founder, CSO and former CEO of the company, has resigned from her acting role as CSO per January 1, 2019. DCprime has appointed Dr Kruisbeek as Chair of the company’s Scientific Advisory Board.

Dr Kruisbeek founded DCprime in 2005 and has since been part of DCprime’s management team. She stepped down as CEO per March 1, 2018 and has continued to act as DCprime’s CSO, to retire per the end of 2018.

Dr Erik Manting, CEO of DCprime states: “Ada Kruisbeek has layed the foundation for DCprime as it is today. Her long career in immuno-oncology has been vital for the company’s scientific direction and academic networks. It has been a pleasure to work together with Ada in the management team throughout the past year and we much appreciate her continued commitment to DCprime via the company’s Scientific Advisory Board.”

Dr Ada Kruisbeek comments: “Since I stepped down a year ago as CEO of DCprime, it has been wonderful to still be involved as CSO of DCprime. It allowed me to witness the progress of the company under the leadership of Erik Manting, plus help where I could to prepare for a smooth transition of the scientific projects. Stepping down now as CSO comes at a time that the company is well-prepared for this, also thanks to the appointment of Dr Satwinder Kaur Singh as the company’s Director of Research.”

About DCprime bv
DCprime is a privately owned, clinical stage biotechnology company focused on cancer immunotherapies. Founded in 2005, DCprime currently develops cell based cancer vaccines based on its proprietary technology platform DCOne®, with lead DCOne® asset DCP-001 being studied in patients with acute myeloid leukemia (AML). A completed Phase I study has demonstrated that DCP-001 is generally safe and capable of inducing a broad immune response. DCprime has received orphan drug designation from the European Medicines Agency for DCP-001 in AML and has commenced a multi-centre Phase II trial. DCprime intends to develop DCOne®-based vaccines in other cancer indications, including multiple myeloma and solid tumours. For more information, visit www.dcprime.com.